期刊文献+

应用AdMax系统构建携带HCV核心基因Core的重组腺病毒载体 被引量:1

Construction of Recombinant Adenovirus Vector with HCV Core Gene by AdMax System
原文传递
导出
摘要 目的应用AdMax系统构建携带丙型肝炎病毒(HCV)核心基因Core的重组腺病毒载体,为进一步研究防止HCV感染的基因疫苗和基因治疗奠定基础。方法RT-PCR法从丙型肝炎患者血清中扩增HCVCore基因,连接到腺病毒穿梭质粒的多克隆位点上,构建重组穿梭质粒pDC315-Core,在脂质体介导下与腺病毒辅助大质粒pBHGlox(delta)E1,3Cre共转染HEK293细胞,包装产生复制缺陷型重组腺病毒pAd-Core,经HEK293细胞扩增后,离子交换柱层析法纯化病毒,测定病毒颗粒数及滴度,并计算比活性及单细胞产量。结果重组腺病毒pAd-Core感染的HEK293细胞经PCR检测,可扩增出HCV核心基因Core片段,经测序证明,其插入序列与设计的HCV Core基因序列一致。扩增纯化后,重组腺病毒的比活性达0.034IU/VP,单细胞产量可达2.63×104VP/细胞。结论已成功构建重组腺病毒载体pAd-Core,为Core基因在腺病毒介导下的基因免疫和基因治疗的研究奠定了基础。 Objective To construct the recombinant adenovirus vector carrying human hepatitis C virus (HCV) Core gene by AdMax system and lay a foundation of further development of gene vaccine against HCV infection as well as gene therapy of HC. Methods HCV Core gene was amplified from the sera of patients with HC by RT-PCR and inserted to the polyclonal site of adenovirus shuttle plasmid pDC315. HEK293 cells were co-transfeeted with the constructed recombinant shuttle plasmid pDC315-Core and large adenovirus helper plasmid pBHGlox (delta) E 1, 3Cre in mediation of liposome. The obtained replication-defective recombinant adenovirus pAd-Core was propagated in HEK293 cells, purified by ion exchange chromatography, counted for virus particles and determined for titer, based on which specific activity and the yield of virus particles in a single cell were calculated. Results HCV Core gene fragment was amplified by PCR from the HEK293 cells transfected with pAd-Core. Sequencing result proved that the inserted sequence was identical to the designed HCV core gene sequence. After propagation and purification, the specific activity and yield of recombinant adenovirus pAd-Core were 0. 034 IU/VP and 2. 63 × 10^4 virus particles per cell respectively. Conclusion Recombinant adenovirus vector pAd-Core was successfully constructed, which provided a basis for application of HCV Core gene to adenovirus-mediated gene immunization and gene therapy.
出处 《中国生物制品学杂志》 CAS CSCD 2009年第6期552-555,共4页 Chinese Journal of Biologicals
关键词 丙型肝炎病毒 Core基因 重组腺病毒 Hepatitis C virus Core gene Recombinant adenovirus
  • 相关文献

参考文献13

  • 1Levine CD, Ghalib RH. Assessment of the patient who failed treatment for chronic hepatitis C. Gastroenterol Nurs, 2005, 28 ($3): S24-S30.
  • 2Nelson AR, Santiago DC, Liz AL, et al. HCV core protein-expressing DNA vaccine induces a strong class I-binding peptide DTH response in mice. Biochem Biophys Res Commun, 2004, 314(3): 781-786.
  • 3Isaguliants MG, Petrakova NV, Kashuba EV, et al. Immunization with hepatitis C virus core gene triggers potent T-cell response, but affects CD4+T-cells. Vaccine, 2004, 22( 13-14): 1656-1665.
  • 4Roohvand F, Aghasadeghi MR, Sadat SM, et al. HCV core protein immunization with Montanide / CpG elicits strong Th1 / Th2 and long-lived CTL responses. Bioehem Biophys Res Commun, 2007, 354(3): 641-649.
  • 5Turturro F. Recombinant adenovirus-mediated cytotoxic gene therapy of lymphoproliferative disorders: is CAR important for the vector to ride. Gene Ther, 2003, 10 (2): 100-104.
  • 6Martin P, Simon B, Lone YC, et al. A vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine, 2008, 26(20): 2471-2481.
  • 7Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against hcterologous virus challenge in chimpanzees. Nature Med, 2006, 12(2): 190-197.
  • 8Shiver JW, Emini EA. Recent advances in the development of HIV- 1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med, 2004, 55: 355-372.
  • 9Danthinne X, hnperiale MJ. Production of first generation adenovirus vectors: a review. Gene Ther, 2000, 7 (20): 1707 -1714.
  • 10Baker AH. Adenoviral vectors for gene therapy. Mol Biotechnol, 2003: 25( 1 ): 101-102.

同被引文献11

  • 1Wang T,Xu J,Yu X,et al.Peroxisome proliferator-activated receptor gamma in malignant diseases[J].Crit Rev Oncol Hematol,2006,58(1):1-14.
  • 2Tontonoz P,Spiegelman BM.Fat and beyond:The diverse biology of PPARgamma[J].Annu Rev Biochem,2008,77:289-312.
  • 3Akiyama TE,Baumann CT,Sakai S,et al.Selective intranuclear redistribution of PPAR isoforms by RXR alpha[J].Mol Endocrinol,2002,16(4):707-721.
  • 4Lapillonne H,Konopleva M,Tsao T,et al.Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acidinduces growth arrest and apoptosis in breast cancer cells[J].Cancer Res,2003,63(18):5926-5939.
  • 5Minguell JJ,Erices A,Conget P.Mesenchymal stem cells[J].Exp Biol Med(Maywood),2001,226(6):507-520.
  • 6Cortesini R.Stem cells,tissue engineering and organogenesis in transplantation[J].Transpl Immunol,2005,15(2):81-89.
  • 7Conrad C,Huss R.Adult stem cell lines in regenerative medicine and reconstructive surgery[J].J Surg Res,2005,124(2):201-208.
  • 8Roorda BD,ter Elst A,Kamps WA,et al.Bone marrow-derived cells and tumor growth:Contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells[J].Crit Rev Oncol Hematol,2009,69 (3):187-198.
  • 9St George JA.Gene therapy progress and prospects:Adenoviral vectors[J].Gene Ther,2003,10(14):1135-1141.
  • 10Sharma A,Li X,Bangari DS,et al.Adenovirus receptors and their implications in gene delivery[J].Virus Res,2009,143(2):184-194.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部